Get started
Author

Kei Oguchi

Observed names: K. Oguchi, KEI OGUCHI
ORCID: 0000-0003-3339-9583
Observed ORCID: 0000-0003-3339-9583
OpenAlex ID: A5077828541
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
2014 · NOZOMU TANAKA, KAZUKI SAKAMOTO, et al. · Oncology Reports · 145
PDF
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA
2015 · KAZUKI SAKAMOTO, TATSUSHI YOKOGAWA, et al. · International Journal of Oncology · 59
PDF
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs
2026 · Monique B. Nilsson, Xiuning Le, et al. · Journal of Thoracic Oncology · 18
TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2019 · Hiroki Irie, Kimihiro Ito, et al. · Molecular Cancer Therapeutics · 15
TAS2940 , a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations
2022 · Kei Oguchi, Hikari Araki, et al. · Cancer Science · 12
PDF
27 TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer
2014 · K. Oguchi, K. Sakamoto, et al. · European Journal of Cancer · 5
Abstract 1783: Trifluorothymidine incorporation into DNA strongly enforces the potential of TAS-102 and leads to remarkably prolonged survival of cancer patients
2012 · Nozomu Tanaka, Kei Oguchi, et al. · Cancer Research · 2
Abstract 4017: TAS2940 inhibits intracranial tumor growth and prolongs survival in HER2-aberrant and EGFR-amplified patient-derived xenograft models
2023 · Jing Han, Mikhila Mahendra, et al. · Cancer Research
Abstract 4008: TAS2940, a novel brain-penetrable pan-ERBB inhibitor, exhibits tumor regression and prolongs survival in intracranial models bearing ERBB aberrations
2023 · Kei Oguchi, Hikari Araki, et al. · Cancer Research
Data from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Figure S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Figure S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
PDF
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Figure S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Figure S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Data from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
2023 · Hiroki Irie, Kimihiro Ito, et al.
Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
2018 · Hiroki Irie, Kei Oguchi, et al. · Molecular Cancer Therapeutics
TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent inhibition for activated mutations of HER2 while sparing EGFR inhibition
2016 · K. Oguchi, H. Irie, et al. · European Journal of Cancer
TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window
2016 · H. Irie, K. Ito, et al. · European Journal of Cancer
Works count: 22
Citation count: 256
H-index: 5
I10-index: 5
Year
Topic
Type